Developer docs
API playgroundTry for free, no card

Search company profiles

ActiGraph

Full company profile

uuid000zffw

Namestring
ActiGraph
Legal namestring
Ametris, L.L.C.
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Ametris (formerly ActiGraph, now a Signant Health Company) provides an end-to-end digital health technology platform for clinical trials, combining FDA-cleared, medical-grade wearable hardware with cloud-based remote monitoring and data analytics. Its core technology stack centers on the ActiGraph LEAP multi-sensor wearable (combining accelerometer, photoplethysmography, skin temperature, and microphone sensors), the CentrePoint cloud platform deployed on AWS and Microsoft Azure, the Ametris Connect patient engagement application (acquired from Biofourmis Connect in January 2025), the ActiLife desktop analysis software, and an Algorithm Marketplace that integrates partner-validated algorithms from empatica (PKG movement-disorder measures), Mobilise-D (gait and mobility), Hyfe (cough detection), and CSEM (PPG-based vital signs). The company has accumulated 30,000+ peer-reviewed publications using its technology, 285+ industry-sponsored clinical trial deployments, and a customer footprint across 150+ countries.

Ametris serves pharmaceutical and biotechnology sponsors (named customers include Pfizer, Takeda, UCB, and Johnson & Johnson), contract research organizations (Parexel), and academic and public-health researchers (Stanford, Johns Hopkins, Harvard, Vanderbilt, University of Alabama at Birmingham). It sells a combination of hardware (LEAP, wGT3X-BT, GT9X Link, CentrePoint Insight Watch, ActiSleep), software subscriptions (CentrePoint, ActiLife), professional services (digital biomarker development, digital endpoint development and biostatistics, DHT regulatory science), algorithm licensing through its marketplace, and managed full-service trial enablement. Pricing is quote-based and not publicly disclosed, with multi-year contracts scoped per study. Distribution combines direct enterprise field sales, an owned e-commerce academic storefront, international resellers in 40+ countries, CRO channel partnerships, and demand generation through the annual ActiGraph Digital Data Summit (ADDS) plus heavy conference presence.

Ametris was founded in 2004 as ActiGraph, rebranded to Ametris in 2024, acquired the Biofourmis Connect life science business in January 2025, and was subsequently acquired by Signant Health. The company is headquartered in Pensacola, Florida, and maintains a PhD-led in-house science team covering data science, biostatistics, and regulatory science. Compliance posture includes FDA-cleared hardware, GDPR-aligned data processing, and EU-U.S., UK Extension, and Swiss-U.S. Data Privacy Framework certifications.

Short descriptiontext

Ametris (formerly ActiGraph, a Signant Health Company) provides FDA-cleared medical-grade wearable devices, a cloud-based remote monitoring platform (CentrePoint), and validated digital measures for clinical trials. It serves pharmaceutical sponsors, CROs, and academic researchers across 150+ countries.

Operating statusenum
Acquired
Ownership categoryenum
akta.pro rankint
HeadquartersPensacola, United States
HQ citystring
Pensacola
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial wearables, digital health technology, remote patient monitoring, medical-grade actigraphy, digital biomarkers platform
Industry5 codes
PRIMARYHLACAOAH
Safety/Pharmacovigilance (PV) & Clinical Safety Systems
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLACAKAG
Specialty Pharmacy & Complex Therapy Management Platforms
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
SECONDARYHLACAEAF
Patient Intake, Digital Registration & eForms
Healthcare & Life Sciences/Digital Health & Health IT/Patient Engagement, CRM & Experience Platforms
SECONDARYHLAGALAC
Signal Detection & Safety Analytics (Epidemiology/RWE)
NAICS code3 codes
  • Custom Computer Programming Services541511
  • Surgical and Medical Instrument Manufacturing339112
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Prepackaged Software7372
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Clinical Trial Digital Health Technology
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Hardware Sales (Wearable Devices)
TypeHardware Sales
Description

Sale of FDA-cleared, medical-grade ActiGraph wearable devices (ActiGraph LEAP, wGT3X-BT, GT9X Link, CentrePoint Insight Watch, ActiSleep) plus device firmware and accessories to academic and clinical customers, distributed via a company-owned e-commerce store and international resellers. FedEx 2-day shipping domestically; international shipments routed through customs with duties paid by recipient. All sales are final with a one-year limited warranty.

ametris.com
2Software & Platform Subscriptions
TypeSubscription Recurring
Description

Licensing of the CentrePoint cloud platform (AWS/Azure-hosted) and the ActiLife desktop software to clinical trial sponsors and academic researchers for device management, real-time data capture, adherence monitoring, and regulatory-grade archiving. Versioned software releases (e.g., CentrePoint v5.3.3.1, ActiLife v7.3.2.0) and CentrePoint Data Hub offered under product-key access.

ametris.com
3Professional Services (Data Analytics & Regulatory Science)
TypeProfessional Services
Description

Consultative fee-based services including digital biomarker development, digital endpoint development and biostatistics, DHT feasibility/usability evaluation, regulatory engagement, content/clinical validity evaluation, fit-for-purpose regulatory dossier development, manuscript development, and statistical analysis plan design for sensor data.

ametris.com
4Algorithm Licensing (Partnership-based)
TypeLicensing Royalties
Description

Licensing and resale of validated third-party algorithms integrated into the Ametris ecosystem (PKG by empatica movement-disorder measures, Mobilise-D gait/mobility measures, Hyfe cough detection, CSEM PPG vital signs), typically packaged with hardware/software offerings.

ametris.com
5Managed / Full-Service Trials Enablement
TypeManaged Services
Description

Operational support services for clinical trials including site training, logistics, data transfer, archiving, and real-time study monitoring for sponsors — a managed-service overlay on top of the DHT technology stack.

ametris.com
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details3 tiers
1Quote-based / Not publicly disclosed
ModelOtherBilling cadenceMulti-year contract
Notes

Enterprise DHT solutions and full-service trial enablement are scoped per study; pricing is not publicly listed. Hardware devices are listed in an academic store with prices not disclosed on the public site.

ametris.com
2Hardware unit sales (actigraphy devices)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Medical-grade wearable devices (ActiGraph LEAP, wGT3X-BT, GT9X Link, CentrePoint Insight Watch, ActiSleep) sold per unit via academic storefront and resellers; FedEx 2-day domestic shipping; international duties paid by recipient; all sales final with one-year limited warranty.

ametris.com
3Professional services (Data Analytics & Regulatory Science)
ModelOutcome Based/ PerformanceBilling cadenceMulti-year contract
Notes

Scoped engagement for digital biomarker development, endpoint/biostatistics, regulatory dossier support, manuscript development, and statistical analysis plan design — priced per project scope rather than disclosed list rates.

ametris.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1CentrePoint®
Description

Remote monitoring platform for clinical trials and scientific research, including CentrePoint® Insight Watch and CentrePoint® Data Hub products.

ametris.com
Core offering1 text field

ActiGraph (now Ametris, a Signant Health Company) provides FDA-cleared, medical-grade wearable hardware (notably the ActiGraph LEAP multi-sensor device) paired with the CentrePoint cloud monitoring platform, ActiLife desktop software, and the Ametris Connect patient engagement app, plus an Algorithm Marketplace of validated third-party algorithms (PKG, Mobilise-D, Hyfe, CSEM PPG). It sells this end-to-end digital health technology stack to pharmaceutical and biotech sponsors, CROs, and academic researchers for use in decentralized and hybrid clinical trials, supported by Data Analytics & Regulatory Science Services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 30,000+ peer-reviewed scientific publications using ActiGraph/Ametris technology
+5 more records
Product overview1 text field

Ametris (formerly ActiGraph, now a Signant Health Company) offers an end-to-end digital health technology (DHT) platform-plus-modules architecture for clinical trials, rather than a single product. The core operational backbone is the CentrePoint Platform, which ingests raw sensor data from FDA-cleared wearable devices — most notably the ActiGraph LEAP multisensor wearable, plus legacy ActiGraph devices such as the CentrePoint Insight Watch, wGT3X-BT, and GT9X Link — and processes it through the ActiLife desktop software and the ActiSync transfer utility. On top of this core, Ametris layers modular offerings: the Ametris Connect patient engagement platform (acquired via the Biofourmis Life Science Business), the Algorithm Marketplace distributing partner-validated algorithms from PKG by empatica, Hyfe, CSEM, and Mobilise-D, the Digital Outcomes and Biomarkers portfolio covering sleep, physical activity, gait, vital signs, and cardinal symptoms, and supporting service lines such as Data Analytics & Regulatory Science Services, the Usability Evaluation Program, Trials Enablement (Adherence Monitoring + Digital Health Operations), and the DECODE research collaborations.

Product and service10 records
1CentrePoint Platform
CategoryCore platform
Description

Scalable cloud remote monitoring and data management platform that ingests raw sensor data from ActiGraph wearables, applies validated digital measures, and serves as the operational backbone for site training, device deployment, real-time study monitoring, and data transfer/archiving in clinical trials.

2ActiGraph LEAP Wearable Device
CategoryWearable device
Description

FDA-cleared, medical-grade, multi-sensor wrist-worn wearable combining accelerometer, gyroscope, PPG, skin temperature, and microphone sensors; the primary hardware feeding CentrePoint and the Algorithm Marketplace with raw data for movement, vital sign, sleep, and respiratory measures.

3CentrePoint Insight Watch
CategoryWearable device
Description

Wrist-worn activity monitor used as a CentrePoint-managed accelerometer device for population health and academic research, with firmware supporting event markers and CPIW accelerometer data in ActiLife 7.

4ActiGraph wGT3X-BT
CategoryWearable device
Description

Bluetooth-enabled wrist/waist/hip activity monitor used in academic research and earlier clinical studies, still supported with downloadable firmware and user manuals on the support downloads page.

5ActiLife Software
CategoryDesktop analysis software
Description

Desktop data analysis and device initialization software (current release v7.3.2.0) used by academic researchers to initialize devices, score raw data, run sleep analysis, validate wear time, and export results.

6ActiSync Software
CategorySync utility software
Description

Companion sync application (current release v3.25.1) used to move data between ActiGraph wearables and a PC, complementing ActiLife and the CentrePoint ecosystem.

7Ametris Connect Platform
CategoryPatient engagement platform
Description

Patient engagement platform integrated into the Ametris Digital Health Technology ecosystem to provide in-app messaging, reminders, and adherence support for trial participants using Ametris wearables.

8Data Analytics & Regulatory Science Services
CategoryProfessional services
Description

Expert services spanning Digital Biomarker Development, Digital Endpoint Development & Biostatistics, and DHT Regulatory Science, including algorithm validation, content/clinical validity, statistical analysis plans for continuous sensor data, manuscript development, and fit-for-purpose regulatory dossiers for sponsors.

9Trials Enablement Services
CategoryManaged trial services
Description

Operational offering combining Adherence Monitoring solutions and Digital Health Operations (site training, logistics, data management, data transfer and archiving, real-time study monitoring) to operationalize DHTs across global clinical trials.

10ActiGraph Academic Storefront
CategoryE-commerce storefront
Description

Owned e-commerce academic store (store.ametris.com) where researchers can purchase ActiGraph LEAP, wGT3X-BT, CentrePoint Insight Watch, and ActiSleep devices, plus download software and firmware.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
1Biofourmis (Biofourmis Connect / Life Science Business)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-01-07
Description

On January 7, 2025 ActiGraph announced the transformational acquisition of the Biofourmis Connect life science business to accelerate clinical trial modernization, strengthen its digital health platform for clinical research with high-precision digital data capture and AI-driven analytics, and support drug development across the lifecycle.

prnewswire.com
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Ametris (formerly ActiGraph) is now a Signant Health Company. Signant Health acquired Ametris to create an end-to-end eCOA and wearables platform that combines deeper patient insights, stronger efficacy evidence, and more streamlined clinical trial execution. Signant is the parent/strategic owner of Ametris.

Strategic tierCoreTypeTechnology or Integration
Description

Ametris has partnered with CSEM to deliver a suite of validated vital sign measures based on photoplethysmography (PPG) data — including heart rate, HRV, respiratory rate, A-Fib detection, and oxygen saturation — alongside accelerometry-based movement outcomes on ActiGraph LEAP devices. CSEM is also a Networking Level Sponsor of ADDS 2025.

Strategic tierCoreTypeTechnology or Integration
Description

Ametris has partnered with PKG by empatica to deliver a suite of clinically validated algorithms for measuring abnormal movements in movement disorders — bradykinesia score, dyskinesia score, percent time tremor, fluctuations score — enabling use of wearable devices for Parkinson's disease, Huntington's disease, and Essential Tremor research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Ametris supports the Mobilise-D device-agnostic, clinically validated digital mobility algorithms (e.g., stride velocity 95th centile, gait speed, cadence) on its hardware/software platform. Mobilise-D is a 5-year, 300+ partner research collaboration advancing digital mobility outcomes for COPD, Parkinson's, MS, and proximal femoral fracture populations.

Strategic tierCoreTypeTechnology or Integration
Description

Ametris has partnered with Hyfe to integrate validated AI-powered cough detection algorithms into the ActiGraph LEAP multi-sensor wearable device alongside Ametris' digital measures for physical activity, sleep, and vital signs, supporting respiratory clinical research.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Ametris partnered with Johnson & Johnson Innovative Medicine to optimize wearable adherence in the global Phase 3 LIBERTAS trial for a metastatic castration-sensitive prostate cancer (mCSPC) therapy. Actigraphy devices were used for more than 12 months to continuously measure sleep quality and physical activity as objective proxies for hot flash burden.

Strategic tierCoreTypeTechnology or Integration
Description

CentrePoint is implemented within the cloud infrastructure of Amazon Web Services (AWS), whose qualifications have been verified by third-party assessments. AWS acts as a subprocessor for personal data hosting, transmission, and storage for clinical trial customers.

9Microsoft Azure
Strategic tierCoreTypeTechnology or Integration
Description

CentrePoint is implemented within the cloud infrastructure of Microsoft Azure, whose qualifications have been verified by third-party assessments. Azure acts as a subprocessor for personal data hosting, transmission, and storage for clinical trial customers.

ametris.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

CSEM serves as a Networking Level Sponsor of the ActiGraph Digital Data Summit (ADDS) 2025, complementing its technology partnership on vital signs measures. CSEM is a public-private Swiss innovation centre developing low-power wireless sensors, signal processing, AI/ML, and ISO 13485-certified digital health technology.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Candice Taguibao, Program Lead at the Digital Medicine Society, presented at the ADDS 2024 Scientific Poster Session — indicating collaborative engagement with the digital medicine community and DHT standards work.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

FedEx is the primary shipping carrier for both domestic (2-day delivery) and international orders; provides shipment tracking, delivery confirmation emails, and is the basis for the shipping policy.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Evidation Health generates real-world evidence from wearable and sensor data for healthcare and research — an emerging player that competes for digital-measure and patient-engagement contracts in clinical research.

TypeBroad incumbent
Description

IQVIA's eCOA and decentralized clinical trial solutions, built on the former Cenduit/Oracle Clinical One platform assets, position it as a broad incumbent competing with the Ametris-Signant stack for pharma wearable DHT and digital endpoint programs.

TypeRegional player
Description

Ypsomed provides connected injection devices and digital therapeutic management platforms primarily in Europe; its wearable-style connected device offerings overlap with Ametris's patient-engagement and adherence offerings in decentralized trials, especially in European sponsor studies.

TypeBroad incumbent
Description

Signant Health is the parent company of Ametris and a leading provider of eCOA, IRT, and patient-centric clinical trial solutions — its broader eCOA platform wraps around Ametris wearables and competes with Clario and Medidata.

TypeEmerging player
Description

Empatica develops its own FDA-cleared EpiMonitor/Embrace wearables and the PKG movement-disorder algorithms that Ametris licenses — a partial competitor whose own hardware overlaps with Ametris LEAP while its algorithms are integrated into Ametris's Algorithm Marketplace.

TypeDirect peer
Description

Clario (formed from the merger of ERT and CRF Health) delivers eCOA, cardiac safety, respiratory, and wearable DHT solutions for clinical trials — directly overlapping with Ametris's eCOA + wearables positioning following Signant Health's acquisition of Ametris.

TypeEmerging player
Description

Koneksa Health provides wearable and digital biomarker solutions for clinical trials, with a comparable focus on validated sensor-based digital endpoints in respiratory, CNS, and rare-disease studies — a focused emerging competitor to Ametris in DHT-enabled trials.

8Biofourmis
TypeDirect peer
Description

Biofourmis is the parent of the Connect life-science business acquired by Ametris in January 2025; its remaining care-delivery franchise is adjacent but the historical Biofourmis platform competed directly with Ametris in wearable-driven decentralized clinical trials.

TypeBroad incumbent
Description

Medidata's Rave Clinical Cloud offers eCOA, sensor data ingestion, and decentralized trial capabilities through its unified platform — a broader clinical-trial technology incumbent that increasingly competes in the same wearable DHT space as Ametris.

TypeDirect peer
Description

VivoSense is a direct peer offering wearable sensor-based digital clinical outcome assessments for clinical trials, with a similar focus on regulatory-grade digital endpoints across therapeutic areas — competing head-to-head for the same pharma/biotech sponsor contracts as Ametris.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses2 records

Each record includes

Headline, Details, Source

Competitive moat7 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration6 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ActiGraph

Clinical Trial Digital Health Technologytheactigraph.com

Ametris (formerly ActiGraph, a Signant Health Company) provides FDA-cleared medical-grade wearable devices, a cloud-based remote monitoring platform (CentrePoint), and validated digital measures for clinical trials. It serves pharmaceutical sponsors, CROs, and academic researchers across 150+ countries.

What ActiGraph does

Ametris (formerly ActiGraph, now a Signant Health Company) provides an end-to-end digital health technology platform for clinical trials, combining FDA-cleared, medical-grade wearable hardware with cloud-based remote monitoring and data analytics. Its core technology stack centers on the ActiGraph LEAP multi-sensor wearable (combining accelerometer, photoplethysmography, skin temperature, and microphone sensors), the CentrePoint cloud platform deployed on AWS and Microsoft Azure, the Ametris Connect patient engagement application (acquired from Biofourmis Connect in January 2025), the ActiLife desktop analysis software, and an Algorithm Marketplace that integrates partner-validated algorithms from empatica (PKG movement-disorder measures), Mobilise-D (gait and mobility), Hyfe (cough detection), and CSEM (PPG-based vital signs). The company has accumulated 30,000+ peer-reviewed publications using its technology, 285+ industry-sponsored clinical trial deployments, and a customer footprint across 150+ countries.

Ametris serves pharmaceutical and biotechnology sponsors (named customers include Pfizer, Takeda, UCB, and Johnson & Johnson), contract research organizations (Parexel), and academic and public-health researchers (Stanford, Johns Hopkins, Harvard, Vanderbilt, University of Alabama at Birmingham). It sells a combination of hardware (LEAP, wGT3X-BT, GT9X Link, CentrePoint Insight Watch, ActiSleep), software subscriptions (CentrePoint, ActiLife), professional services (digital biomarker development, digital endpoint development and biostatistics, DHT regulatory science), algorithm licensing through its marketplace, and managed full-service trial enablement. Pricing is quote-based and not publicly disclosed, with multi-year contracts scoped per study. Distribution combines direct enterprise field sales, an owned e-commerce academic storefront, international resellers in 40+ countries, CRO channel partnerships, and demand generation through the annual ActiGraph Digital Data Summit (ADDS) plus heavy conference presence.

Ametris was founded in 2004 as ActiGraph, rebranded to Ametris in 2024, acquired the Biofourmis Connect life science business in January 2025, and was subsequently acquired by Signant Health. The company is headquartered in Pensacola, Florida, and maintains a PhD-led in-house science team covering data science, biostatistics, and regulatory science. Compliance posture includes FDA-cleared hardware, GDPR-aligned data processing, and EU-U.S., UK Extension, and Swiss-U.S. Data Privacy Framework certifications.

ActiGraph firmographics

Firmographics
Name
ActiGraph
Legal name
Ametris, L.L.C.
Website
https://theactigraph.com
Company type
Private
Founded year
2004
Operating status
Acquired
Short description
Ametris (formerly ActiGraph, a Signant Health Company) provides FDA-cleared medical-grade wearable devices, a cloud-based remote monitoring platform (CentrePoint), and validated digital measures for clinical trials. It serves pharmaceutical sponsors, CROs, and academic researchers across 150+ countries.
Ownership category
akta.pro rank

ActiGraph industry classification

Industry
Product category
Clinical Trial Digital Health Technology
NAICS
Custom Computer Programming Services (541511), Surgical and Medical Instrument Manufacturing (339112), Scientific Research and Development Services (5417)
SIC
Services-Prepackaged Software (7372), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLACAOAH
Safety/Pharmacovigilance (PV) & Clinical Safety Systems
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLACAKAG
Specialty Pharmacy & Complex Therapy Management Platforms
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
SECONDARYHLACAEAF
Patient Intake, Digital Registration & eForms
Healthcare & Life Sciences/Digital Health & Health IT/Patient Engagement, CRM & Experience Platforms
SECONDARYHLAGALAC
Signal Detection & Safety Analytics (Epidemiology/RWE)

Keywords

  • Clinical trial wearables
  • Digital health technology
  • Remote patient monitoring
  • Medical-grade actigraphy
  • Digital biomarkers platform

Where ActiGraph is headquartered

Location

Headquarters

HQ city
Pensacola
HQ country
United States
HQ region
North America

Offices3 records

Markets served

ActiGraph business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Hardware Sales (Wearable Devices): Sale of FDA-cleared, medical-grade ActiGraph wearable devices (ActiGraph LEAP, wGT3X-BT, GT9X Link, CentrePoint Insight Watch, ActiSleep) plus device firmware and accessories to academic and clinical customers, distributed via a company-owned e-commerce store and international resellers. FedEx 2-day shipping domestically; international shipments routed through customs with duties paid by recipient. All sales are final with a one-year limited warranty.
  2. Software & Platform Subscriptions: Licensing of the CentrePoint cloud platform (AWS/Azure-hosted) and the ActiLife desktop software to clinical trial sponsors and academic researchers for device management, real-time data capture, adherence monitoring, and regulatory-grade archiving. Versioned software releases (e.g., CentrePoint v5.3.3.1, ActiLife v7.3.2.0) and CentrePoint Data Hub offered under product-key access.
  3. Professional Services (Data Analytics & Regulatory Science): Consultative fee-based services including digital biomarker development, digital endpoint development and biostatistics, DHT feasibility/usability evaluation, regulatory engagement, content/clinical validity evaluation, fit-for-purpose regulatory dossier development, manuscript development, and statistical analysis plan design for sensor data.
  4. Algorithm Licensing (Partnership-based): Licensing and resale of validated third-party algorithms integrated into the Ametris ecosystem (PKG by empatica movement-disorder measures, Mobilise-D gait/mobility measures, Hyfe cough detection, CSEM PPG vital signs), typically packaged with hardware/software offerings.
  5. Managed / Full-Service Trials Enablement: Operational support services for clinical trials including site training, logistics, data transfer, archiving, and real-time study monitoring for sponsors — a managed-service overlay on top of the DHT technology stack.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based / Not publicly disclosed
Unit PricingPay-as-you-goHardware unit sales (actigraphy devices)
Outcome Based/ PerformanceMulti-year contractProfessional services (Data Analytics & Regulatory Science)

Go-to-market motion3 records

Distribution channels5 records

Marketing channels10 records

ActiGraph product offering

Product offering

Core offering

ActiGraph (now Ametris, a Signant Health Company) provides FDA-cleared, medical-grade wearable hardware (notably the ActiGraph LEAP multi-sensor device) paired with the CentrePoint cloud monitoring platform, ActiLife desktop software, and the Ametris Connect patient engagement app, plus an Algorithm Marketplace of validated third-party algorithms (PKG, Mobilise-D, Hyfe, CSEM PPG). It sells this end-to-end digital health technology stack to pharmaceutical and biotech sponsors, CROs, and academic researchers for use in decentralized and hybrid clinical trials, supported by Data Analytics & Regulatory Science Services.

Product overview

Ametris (formerly ActiGraph, now a Signant Health Company) offers an end-to-end digital health technology (DHT) platform-plus-modules architecture for clinical trials, rather than a single product. The core operational backbone is the CentrePoint Platform, which ingests raw sensor data from FDA-cleared wearable devices — most notably the ActiGraph LEAP multisensor wearable, plus legacy ActiGraph devices such as the CentrePoint Insight Watch, wGT3X-BT, and GT9X Link — and processes it through the ActiLife desktop software and the ActiSync transfer utility. On top of this core, Ametris layers modular offerings: the Ametris Connect patient engagement platform (acquired via the Biofourmis Life Science Business), the Algorithm Marketplace distributing partner-validated algorithms from PKG by empatica, Hyfe, CSEM, and Mobilise-D, the Digital Outcomes and Biomarkers portfolio covering sleep, physical activity, gait, vital signs, and cardinal symptoms, and supporting service lines such as Data Analytics & Regulatory Science Services, the Usability Evaluation Program, Trials Enablement (Adherence Monitoring + Digital Health Operations), and the DECODE research collaborations.

Differentiator

Problem solved

Functional benefit

Brands

  • CentrePoint®: Remote monitoring platform for clinical trials and scientific research, including CentrePoint® Insight Watch and CentrePoint® Data Hub products.

Products and services

  • CentrePoint Platform Scalable cloud remote monitoring and data management platform that ingests raw sensor data from ActiGraph wearables, applies validated digital measures, and serves as the operational backbone for site training, device deployment, real-time study monitoring, and data transfer/archiving in clinical trials.
  • ActiGraph LEAP Wearable Device FDA-cleared, medical-grade, multi-sensor wrist-worn wearable combining accelerometer, gyroscope, PPG, skin temperature, and microphone sensors; the primary hardware feeding CentrePoint and the Algorithm Marketplace with raw data for movement, vital sign, sleep, and respiratory measures.
  • CentrePoint Insight Watch Wrist-worn activity monitor used as a CentrePoint-managed accelerometer device for population health and academic research, with firmware supporting event markers and CPIW accelerometer data in ActiLife 7.
  • ActiGraph wGT3X-BT Bluetooth-enabled wrist/waist/hip activity monitor used in academic research and earlier clinical studies, still supported with downloadable firmware and user manuals on the support downloads page.
  • ActiLife Software Desktop data analysis and device initialization software (current release v7.3.2.0) used by academic researchers to initialize devices, score raw data, run sleep analysis, validate wear time, and export results.
  • ActiSync Software Companion sync application (current release v3.25.1) used to move data between ActiGraph wearables and a PC, complementing ActiLife and the CentrePoint ecosystem.
  • Ametris Connect Platform Patient engagement platform integrated into the Ametris Digital Health Technology ecosystem to provide in-app messaging, reminders, and adherence support for trial participants using Ametris wearables.
  • Data Analytics & Regulatory Science Services Expert services spanning Digital Biomarker Development, Digital Endpoint Development & Biostatistics, and DHT Regulatory Science, including algorithm validation, content/clinical validity, statistical analysis plans for continuous sensor data, manuscript development, and fit-for-purpose regulatory dossiers for sponsors.
  • Trials Enablement Services Operational offering combining Adherence Monitoring solutions and Digital Health Operations (site training, logistics, data management, data transfer and archiving, real-time study monitoring) to operationalize DHTs across global clinical trials.
  • ActiGraph Academic Storefront Owned e-commerce academic store (store.ametris.com) where researchers can purchase ActiGraph LEAP, wGT3X-BT, CentrePoint Insight Watch, and ActiSleep devices, plus download software and firmware.

Quantifiable outcome

  • 30,000+ peer-reviewed scientific publications using ActiGraph/Ametris technology
  • +5 more outcomes

Companies that use ActiGraph

Customer profile

Named customers10 records

Segments5 records

Ideal customer profiles4 records

ActiGraph technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability3 records

Feature9 records

ActiGraph partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered flagship, core, major and minor.

  • Biofourmis (Biofourmis Connect / Life Science Business)flagshipStrategic or Co-development Partner · 7 January 2025On January 7, 2025 ActiGraph announced the transformational acquisition of the Biofourmis Connect life science business to accelerate clinical trial modernization, strengthen its digital health platform for clinical research with high-precision digital data capture and AI-driven analytics, and support drug development across the lifecycle.
  • Signant HealthflagshipStrategic or Co-development PartnerAmetris (formerly ActiGraph) is now a Signant Health Company. Signant Health acquired Ametris to create an end-to-end eCOA and wearables platform that combines deeper patient insights, stronger efficacy evidence, and more streamlined clinical trial execution. Signant is the parent/strategic owner of Ametris.
  • CSEM (Swiss Centre for Microelectronics and Microtechnology)coreTechnology or IntegrationAmetris has partnered with CSEM to deliver a suite of validated vital sign measures based on photoplethysmography (PPG) data — including heart rate, HRV, respiratory rate, A-Fib detection, and oxygen saturation — alongside accelerometry-based movement outcomes on ActiGraph LEAP devices. CSEM is also a Networking Level Sponsor of ADDS 2025.
  • PKG by empaticacoreTechnology or IntegrationAmetris has partnered with PKG by empatica to deliver a suite of clinically validated algorithms for measuring abnormal movements in movement disorders — bradykinesia score, dyskinesia score, percent time tremor, fluctuations score — enabling use of wearable devices for Parkinson's disease, Huntington's disease, and Essential Tremor research.
  • Mobilise-D ConsortiumcoreStrategic or Co-development PartnerAmetris supports the Mobilise-D device-agnostic, clinically validated digital mobility algorithms (e.g., stride velocity 95th centile, gait speed, cadence) on its hardware/software platform. Mobilise-D is a 5-year, 300+ partner research collaboration advancing digital mobility outcomes for COPD, Parkinson's, MS, and proximal femoral fracture populations.
  • HyfecoreTechnology or IntegrationAmetris has partnered with Hyfe to integrate validated AI-powered cough detection algorithms into the ActiGraph LEAP multi-sensor wearable device alongside Ametris' digital measures for physical activity, sleep, and vital signs, supporting respiratory clinical research.
  • Johnson & Johnson Innovative MedicinemajorStrategic or Co-development PartnerAmetris partnered with Johnson & Johnson Innovative Medicine to optimize wearable adherence in the global Phase 3 LIBERTAS trial for a metastatic castration-sensitive prostate cancer (mCSPC) therapy. Actigraphy devices were used for more than 12 months to continuously measure sleep quality and physical activity as objective proxies for hot flash burden.
  • Amazon Web Services (AWS)coreTechnology or IntegrationCentrePoint is implemented within the cloud infrastructure of Amazon Web Services (AWS), whose qualifications have been verified by third-party assessments. AWS acts as a subprocessor for personal data hosting, transmission, and storage for clinical trial customers.
  • Microsoft AzurecoreTechnology or IntegrationCentrePoint is implemented within the cloud infrastructure of Microsoft Azure, whose qualifications have been verified by third-party assessments. Azure acts as a subprocessor for personal data hosting, transmission, and storage for clinical trial customers.
  • CSEM (ADDS Networking Level Sponsor)minorGTM or Marketing PartnerCSEM serves as a Networking Level Sponsor of the ActiGraph Digital Data Summit (ADDS) 2025, complementing its technology partnership on vital signs measures. CSEM is a public-private Swiss innovation centre developing low-power wireless sensors, signal processing, AI/ML, and ISO 13485-certified digital health technology.
  • Digital Medicine Society (DiMe)minorStrategic or Co-development PartnerCandice Taguibao, Program Lead at the Digital Medicine Society, presented at the ADDS 2024 Scientific Poster Session — indicating collaborative engagement with the digital medicine community and DHT standards work.
  • FedExminorChannel Partner/ Reseller/ DistributorFedEx is the primary shipping carrier for both domestic (2-day delivery) and international orders; provides shipment tracking, delivery confirmation emails, and is the basis for the shipping policy.

Scale indicators8 records

Recent moves6 records

Expansion highlights7 records

ActiGraph competitors and assessment

Company assessment

Emerging players

  • Evidation Health: Evidation Health generates real-world evidence from wearable and sensor data for healthcare and research — an emerging player that competes for digital-measure and patient-engagement contracts in clinical research.
  • Empatica: Empatica develops its own FDA-cleared EpiMonitor/Embrace wearables and the PKG movement-disorder algorithms that Ametris licenses — a partial competitor whose own hardware overlaps with Ametris LEAP while its algorithms are integrated into Ametris's Algorithm Marketplace.
  • Koneksa Health: Koneksa Health provides wearable and digital biomarker solutions for clinical trials, with a comparable focus on validated sensor-based digital endpoints in respiratory, CNS, and rare-disease studies — a focused emerging competitor to Ametris in DHT-enabled trials.

Broad incumbents

  • IQVIA (Clinical Technologies): IQVIA's eCOA and decentralized clinical trial solutions, built on the former Cenduit/Oracle Clinical One platform assets, position it as a broad incumbent competing with the Ametris-Signant stack for pharma wearable DHT and digital endpoint programs.
  • Signant Health: Signant Health is the parent company of Ametris and a leading provider of eCOA, IRT, and patient-centric clinical trial solutions — its broader eCOA platform wraps around Ametris wearables and competes with Clario and Medidata.
  • Medidata (Dassault Systèmes): Medidata's Rave Clinical Cloud offers eCOA, sensor data ingestion, and decentralized trial capabilities through its unified platform — a broader clinical-trial technology incumbent that increasingly competes in the same wearable DHT space as Ametris.

Regional players

  • Ypsomed (YpsoMate / YDS / mySmartShare): Ypsomed provides connected injection devices and digital therapeutic management platforms primarily in Europe; its wearable-style connected device offerings overlap with Ametris's patient-engagement and adherence offerings in decentralized trials, especially in European sponsor studies.

Direct peers

  • Clario: Clario (formed from the merger of ERT and CRF Health) delivers eCOA, cardiac safety, respiratory, and wearable DHT solutions for clinical trials — directly overlapping with Ametris's eCOA + wearables positioning following Signant Health's acquisition of Ametris.
  • Biofourmis: Biofourmis is the parent of the Connect life-science business acquired by Ametris in January 2025; its remaining care-delivery franchise is adjacent but the historical Biofourmis platform competed directly with Ametris in wearable-driven decentralized clinical trials.
  • VivoSense: VivoSense is a direct peer offering wearable sensor-based digital clinical outcome assessments for clinical trials, with a similar focus on regulatory-grade digital endpoints across therapeutic areas — competing head-to-head for the same pharma/biotech sponsor contracts as Ametris.

Market position

Strengths5 records

Weaknesses2 records

Competitive moat7 records

Key risks6 records

Key highlights6 records

Customer concentration

ActiGraph social profiles

Digital presence

ActiGraph compliance and trust

Trust signal

Compliance3 records

ActiGraph financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ActiGraph leadership team

Management profile

Number of profiles

Profiles7 records

ActiGraph subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

ActiGraph funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ActiGraph M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ActiGraph

What does ActiGraph do?

ActiGraph (now Ametris, a Signant Health Company) provides FDA-cleared, medical-grade wearable hardware (notably the ActiGraph LEAP multi-sensor device) paired with the CentrePoint cloud monitoring platform, ActiLife desktop software, and the Ametris Connect patient engagement app, plus an Algorithm Marketplace of validated third-party algorithms (PKG, Mobilise-D, Hyfe, CSEM PPG). It sells this end-to-end digital health technology stack to pharmaceutical and biotech sponsors, CROs, and academic researchers for use in decentralized and hybrid clinical trials, supported by Data Analytics & Regulatory Science Services.

Is ActiGraph a public or private company?

ActiGraph is a private company. It is classified as corporate owned and is currently acquired.

When was ActiGraph founded?

ActiGraph was founded in 2004.

Where is ActiGraph based?

ActiGraph is headquartered in Pensacola, United States, in the North America region.

How does ActiGraph make money?

Five revenue lines are on record. Hardware Sales (Wearable Devices) is the primary driver. The others are software & Platform Subscriptions, professional Services (Data Analytics & Regulatory Science), algorithm Licensing (Partnership-based) and managed / Full-Service Trials Enablement.

Who are ActiGraph's main competitors?

Emerging players on record are Evidation Health, Empatica and Koneksa Health. Broad incumbents are IQVIA (Clinical Technologies), Signant Health and Medidata (Dassault Systèmes). Ypsomed (YpsoMate / YDS / mySmartShare) is listed as a regional player. Direct peers are Clario, Biofourmis and VivoSense.

Does ActiGraph have an API?

No public API is recorded for ActiGraph.

What industry is ActiGraph in?

ActiGraph's product category is Clinical Trial Digital Health Technology. Its primary akta.pro industry code is HLACAOAH, Safety/Pharmacovigilance (PV) & Clinical Safety Systems, with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 541511 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Cambridge CognitionActigraphy and wearable sensor technologies to enhance assessment in health conditionsThe 2025 ActiGraph Digital Data Summit in Pensacola, FL, featured presentations on actigraphy and wearable sensors for assessing motor function and behavior. A pre-conference ALS workshop discussed evidence generation and regulatory approval, with survey data showing patient support for actigraphy in ALS trials. The author expressed optimism about the field's future.Clinical LeaderModernizing Clinical Research With AI And Digital Data: ActiGraph's Acquisition Of Biofourmis ConnectAmetris, formerly known as ActiGraph, is hosting a webinar to discuss its recent acquisition of the Biofourmis Connect platform. The presentation outlines how integrating this AI and digital data technology aims to enhance clinical trial efficiency and provide deeper insights into therapeutic efficacy and safety. This strategic move positions the company to optimize patient outcomes in the evolving digital health landscape.TheactigraphActiGraph Accelerates Clinical Trial Modernization with Transformational Acquisition of Biofourmis Life Science BusinessActiGraph acquired Biofourmis Connect, an AI-driven digital trial platform for life sciences, to modernize clinical research. The combined solution integrates ActiGraph's LEAP wearable with other medical-grade devices and adds AI analytics. The acquisition expands ActiGraph's support for biopharma clients across the drug-product lifecycle.STATWearable maker ActiGraph acquires assets from Biofourmis to boost clinical trial offeringsActiGraph acquired Biofourmis' life sciences business, an eight-figure deal including software and algorithms. The acquisition adds capabilities to measure blood pressure, weight, blood oxygen, and ECG, and to monitor protocol adherence and patient-reported outcomes. ActiGraph aims to become a clearinghouse for drug developers using digital tools in clinical trials.HIT ConsultantActiGraph Acquires Biofourmis Life Science BusinessActiGraph acquired Biofourmis Connect, a division of Biofourmis specializing in AI-powered digital trial platforms for life science. Financial terms were not disclosed. The acquisition combines ActiGraph's wearable technology with Biofourmis Connect's analytics to create a device-agnostic platform for clinical research.YahooActiGraph Accelerates Clinical Trial Modernization with Transformational Acquisition of Biofourmis Life Science BusinessActiGraph acquired Biofourmis Connect, an AI-driven digital trial platform for life sciences, to modernize clinical research. The combined solution integrates ActiGraph's LEAP wearable with other medical-grade devices and adds AI analytics for pain and CRS risk assessment. The deal expands ActiGraph's device-agnostic platform and supports biopharma clients across the drug-product lifecycle.PR NewswireActiGraph Accelerates Clinical Trial Modernization with Transformational Acquisition of Biofourmis Life Science BusinessActiGraph acquired Biofourmis Connect, an AI-driven digital trial platform for life sciences, to modernize clinical research. The combined solution integrates ActiGraph's wearable devices with Biofourmis' platform, targeting applications like pain assessment and CRS risk prediction. The acquisition expands ActiGraph's device-agnostic platform and supports biopharma clients across the drug-product lifecycle.BiofourmisActiGraph Accelerates Clinical Trial Modernization with Transformational Acquisition of Biofourmis Life Science BusinessActiGraph has announced the acquisition of Biofourmis Connect, aiming to develop a comprehensive digital health and clinical trial platform. This integration enhances ActiGraph's offerings with AI-driven analytics and device-agnostic solutions, supporting clinical research and real-world patient care. The move is part of ActiGraph's broader strategy to lead digital transformation in clinical development and healthcare.YahooGlobal Digital Biomarkers Market Outlook Report 2024-2029 Featuring Prominent Vendors - ActiGraph, AliveCor, Amgen, Biogen, and Koneksa HealthThe global digital biomarkers market was valued at USD 2.49 billion in 2023 and is projected to reach $8.59 billion by 2029, a CAGR of 22.86%. North America held over 46% of the market share in 2023, with wearables and sensors leading the product segment.PR NewswireFoundational V3 Framework Extended to Incorporate Usability Validation of Sensor-Based Digital Health TechnologiesThe Digital Medicine Society (DiMe) and its Digital Health Measurement Collaborative Community (DATAcc) released V3+, an extension of its foundational V3 Framework for sensor-based digital health technologies, adding a fourth component of "Usability Validation" to evaluate user experience at scale. The original three-component V3 Framework has been accessed over 30,000 times, cited more than 250 times in peer-reviewed journals, and leveraged by over 140 teams including NIH, FDA, and EMA. Twelve project partners including AARDEX Group, ActiGraph, Genentech, Janssen, Regeneron, and others participated in developing V3+ and supporting resources.